HOUSTON - November 10 - In a move considered historic by supporters of medical marijuana, the American Medical Association's House of Delegates today adopted a new policy position calling for the review of marijuana's status as a Schedule I drug in the federal Controlled Substances Act. The old language in Policy H-95.952 had previously recommended that "marijuana be retained in Schedule I," which groups marijuana with drugs such as heroin, LSD and PCP that are deemed to have no accepted medical uses and to be unsafe for use even under medical supervision.

The revised policy, adopted today, states, "Our AMA urges that marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods." It goes on to explain that this position should not be construed as an endorsement of state medical marijuana programs.

"This shift, coming from what has historically been America's most cautious and conservative major medical organization, is historic," said Aaron Houston, director of government relations for the Marijuana Policy Project, who attended the AMA meeting. "Marijuana's Schedule I status is not just scientifically untenable, given the wealth of recent data showing it to be both safe and effective for chronic pain and other conditions, but it's been a major obstacle to needed research."

Drugs listed in Schedule II, for which medical use is permitted with strict controls, include cocaine, morphine and methamphetamine. A pill containing THC, the component responsible for marijuana's "high," is classed in Schedule III, whose looser requirements allow phoned-in prescriptions.